Lack of data leads to double NICE no for Novartis's Glivec
This article was originally published in Scrip
NICE, the National Institute for health and Clinical Excellence in the UK, is set to decline NHS funding for high doses of Novartis's Glivec (imatinib) for treating unresectable and or metastatic gastrointestinal stromal tumors (GIST), it says in preliminary draft guidance published today. It based the decision on a lack of "good quality clinical and cost-effectiveness data".
You may also be interested in...
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.
In an exclusive interview, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.